Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.
about
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomasBruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibB cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewA Methyl 4-Oxo-4-phenylbut-2-enoate with in Vivo Activity against MRSA that Inhibits MenB in the Bacterial Menaquinone Biosynthesis PathwayA quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacyFuture therapeutic targets in rheumatoid arthritis?Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumabBruton's TK inhibitors: structural insights and evolution of clinical candidates.Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myelomaProlonged and tunable residence time using reversible covalent kinase inhibitors.CNS Anticancer Drug Discovery and Development Conference White Paper.Signal transduction and chemotaxis in mast cellsOptimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression.Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.Hairy cell leukemia - immunotargets and therapiesDiscovery of a BTK/MNK dual inhibitor for lymphoma and leukemiaKinase inhibitors as potential agents in the treatment of multiple myeloma.Ibrutinib and novel BTK inhibitors in clinical development.Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).Targeted therapy for chronic lymphocytic leukemia: current status and future directions.BTK Signaling in B Cell Differentiation and Autoimmunity.New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.Breakthrough therapies in B-cell non-Hodgkin lymphoma.The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy.Targeting of B-cell receptor signalling in B-cell malignancies.Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanismFrom identification of the BTK kinase to effective management of leukemia.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.Phenotypic Approaches to Identify Inhibitors of B Cell Activation.Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor.Magic pills: new oral drugs to treat chronic lymphocytic leukemia.A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
P2860
Q26991890-0DBECFD8-B473-493D-AFB2-3377AF7B14A7Q26995113-4A17CA9E-542E-47B2-BAB5-1FF9A6ADFBA4Q27009550-106ECC0B-943C-4C36-BE95-17D21FCD004BQ27304386-6C19622A-81E4-4E36-821C-835603524031Q28396297-D4639C48-CE78-4D65-9A74-B0861DB2B0C3Q33636442-5E2FAAC4-2B31-4F1C-8B64-A01961050401Q33841419-05F46FC8-5C17-4317-B8F9-F6EE81B1E880Q34039406-35EA8DB0-5DCC-40D5-BB62-18E518310423Q35076449-7FE90B02-285D-41E4-B627-9707752E0D67Q35181271-2256ECD3-AC3E-4C4B-9141-15B438D354EAQ35260732-7794465B-88C4-4440-A758-D447268C0DC7Q35756228-6DFB4899-9F0A-4ABA-91A5-402F75F6693CQ36089590-6F1001F7-3A76-4B20-9F3D-19A1426544D9Q36240848-C095DA7D-0508-4E44-A9CB-1B71331C2386Q36635267-F9C69DE8-2BE3-4223-9FFB-40A0AF2054B0Q36888218-5522D43E-607E-40FC-8E76-C82A180873A3Q37031666-9ADC91E8-D2A3-42B9-89A5-FEDA45D4FE90Q37180382-E4AFAAAC-5429-495F-AD2E-DB593B22D381Q37697253-061812CD-0223-4788-9C6C-86D616F366B7Q38130010-1CD41DF6-DB9B-4F1C-BA15-F4390AD1D7C3Q38225805-6D274C65-F8BE-4267-9AFA-2A9DE5CC62C9Q38331701-771B04FA-D341-46C1-AFE5-8D66ECC37D2AQ38581000-BE0AB6AB-FD97-4218-B348-CF48E758A862Q38646974-4883C917-4BBB-4830-BE2B-7AEF0A65E937Q38668551-BF72647F-9A66-477D-A9F9-EB9DA113CB00Q38697262-3CDDBD15-37DA-428C-8FC9-75D2A4FA85EEQ38708600-5CE85096-35EE-4583-A9CE-599F89582694Q38728631-3B8EF916-3E36-42F6-AD62-DA44ED8D2A5CQ38744922-C161CFF0-737A-48E9-891C-C0BA8CDE25C0Q38815360-50C47F55-B147-45E5-9A29-15E71EF109B0Q38817591-DA43DC85-FF9F-4685-88EC-FD9F54ABA783Q38819164-1450D536-1B77-43FA-99A0-D1D08D02A5E3Q38826405-80CE6B26-4DBB-44D7-8A8F-1496CC154BAAQ38834459-AE3E1D57-4998-4FA8-A7E9-E1933136D132Q38857067-214E70D8-5FB1-4820-B6FA-C9E1AF516D03Q38878317-ABF068C2-74E4-4234-ADF0-657B5F1D61B1Q38924086-B1F96EC3-191D-46EE-A13B-010B67AA6E2FQ38938436-89531A5F-1210-47E7-AE62-E85E03672F8FQ38943877-27287583-65E6-46E7-A9E5-D9235FF93DD3Q39024879-586941A5-0953-4ABC-BC28-3A8860888FD2
P2860
Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Inhibition of Btk with CC-292 ...... f activity in mice and humans.
@en
Inhibition of Btk with CC-292 ...... f activity in mice and humans.
@nl
type
label
Inhibition of Btk with CC-292 ...... f activity in mice and humans.
@en
Inhibition of Btk with CC-292 ...... f activity in mice and humans.
@nl
prefLabel
Inhibition of Btk with CC-292 ...... f activity in mice and humans.
@en
Inhibition of Btk with CC-292 ...... f activity in mice and humans.
@nl
P2093
P356
P1476
Inhibition of Btk with CC-292 ...... f activity in mice and humans.
@en
P2093
Alex Dubrovskiy
Erica K Evans
Heather Lounsbury
Hormoz Mazdiyasni
Juswinder Singh
Mariana Nacht
Martin I Freed
Matthew T Labenski
Michael Sheets
Prasoon Chaturvedi
P304
P356
10.1124/JPET.113.203489
P407
P577
2013-05-24T00:00:00Z